LARGON
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARGON is an injectable NDA-approved product sponsored by Hikma with approval dating to December 1960. The mechanism of action, pharmacologic class, and specific indications are not publicly documented in available data. As a legacy injectable, LARGON likely serves a specialized clinical niche with established but limited modern utilization.
LOE Approaching
With LOE approaching and zero linked job openings, this product faces significant commercial headwinds; the brand team is likely minimal or transitioning resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LARGON presents minimal career development opportunity; with zero linked job openings and LOE approaching, roles are concentrated in legacy product management and operational wind-down. Career growth on this asset is not recommended for early-to-mid career professionals seeking advancement.
Supply Chain ManagerRegulatory Affairs Specialist
Worked on LARGON at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.